存活蛋白与肿瘤标记物

存活蛋白是凋亡抑制蛋白家族中的一个成员,具有抑制细胞凋亡,调节细胞分裂和促进血管生成等多种功能且在多种肿瘤细胞中高表达.本文总结了存活蛋白的分子结构特征,亚细胞分布,生物学功能及其和癌症发生发展的关系,重点分析了存活蛋白作为肿瘤标记物的研究现状和潜在价值.     

Polo like 激酶在细胞分裂中的功能研究进展

polo like激酶（plks)是广泛存在于真核生物中的一类丝/苏氨酸蛋白激酶,其结构和功能都十分保守,许多研究表明,plks家族成员在细胞分裂过程中发挥着重要作用,细胞分裂开始时,plks可以推动细胞完成G2/M期转化,很可能是细胞开始分裂的开关之一,并有望成为抑制癌症的靶位点,它的作用涉及到中心体的成熟,纺锤体的组织,以及成熟促进因子（MPF）的激活,当细胞分裂进入中后期时,plks又能够激活后期促进复合体（APC）,降解cycling蛋白,促进姐妹染色体分开,使分裂进入后期,当细胞分裂进入末期时,plks又能促进胞质分裂,本文拟对plks在细胞分裂中的作用作一简要介绍。     

癌症与细胞分裂的关系

几乎一个多世纪以前首次提出的一个关于癌症始发机制的假设经受住了时间的考验。当时,德国生物学家Theodor Boveri提出．细胞分裂的失败可能会产生四倍体细胞（含有双份的染色体）,后者然后进行多极有丝分裂,导致可诱发癌症的基因组不稳定性。Fujiwara等人通过用一个肌动蛋白抑制因子来阻断细胞分裂、产生四倍体细胞的方式验证了这一假设。所获得的细胞在试管中能发生转化,还能在小鼠身上自发产生肿瘤。转化的细胞表现出很强的基因组不稳定性．其中包括一个含有与乳腺癌有关基因的区域的扩大。     

细胞周期因子与植物根系发育

植物根系的发育是一个非常复杂且被精确调控的过程,受到多种信号的调控,其中对细胞分裂水平调控的研究已经成为细胞生物学研究的热点之一.文章介绍了植物细胞周期因子和植物根系发育相关的细胞周期调控机制以及根系细胞周期激素调节的研究进展.     

PPARs信号通路与哺乳动物生殖

过氧化物酶体增殖因子活化受体(peroxisome proliferator-activated receptors,PPARs)在动物体内有着广泛的生物学作用,可调节脂类代谢、能量收支平衡以及细胞分裂分化等重要生理过程。已经发现,PPARs信号通路与糖尿病和癌症等许多重大疾病的发生有关。随着基因剔除技术的应用以及PPARs人工配体的开发利用,人们对PPARs的认识不断深入。现对PPARs通路在卵巢周期、黄体形成、胚胎着床、胎盘发育和雄性生殖等哺乳动物生殖系统中的表达、功能及作用机制进行综述。     

细胞周期蛋白Cdc25C的研究

细胞分裂周期蛋白25同源蛋白C(cell division cyclin 25 homolog C,Cdc25C)是一种细胞分裂周期蛋白质,在真核生物的细胞有丝分裂中起重要调节作用,是控制细胞周期进入M期的关键因子之一。在对Cdc25C的研究过程中,人们逐渐认识到细胞周期调节物可能对于癌症治疗是一个潜在的靶物质。Cdc25CC表达量的变化与肿瘤的发生机制有关。更重要的是,Cdc25C被发现是一种新的肿瘤相关抗原。     

癌症研究的生物信息学资源

随着癌症研究的发展,生物信息学成为癌症研究的一个非常重要的方法和手段,本文从微阵列芯片数据管理和分析软件、微阵列数据仓库、蛋白质功能预测工具和蛋白质结构预测工具等四个方面介绍癌症研究的生物信息学资源信息,以给相关研究提供帮助.     

高等植物的雄核发育

雄核发育的过程可以人为划分为3个阶段：小孢子胚性潜能的获得、细胞分裂的起始和胚胎的分化形成。文章介绍每一阶段所发生的细胞和分子水平的变化,其中侧重点在基因表达的变化,包括转录因子基因、与胁迫有关的蛋白质基因、淀粉合成及蛋白质分解相关基因以及近年来发现的与胚胎发生有关的调节基因的研究进展。     

柑桔果实采后枯水的机理

本文概述柑桔果实发生枯水时呼吸作用、营养物质、细胞形态特征等的生理变化以及与枯水发生有关的因素。分析了枯水机理研究中有待解决的问题。认为贮藏过程中果皮细胞分裂和生长,从而导致营养物质消耗是枯水发生的根本原因。     

p300/CBP及其相关因子PCAF与转录调控

p300/CBP及相关因子PCAF具有乙酰转移酶活性,能通过乙酰化组蛋白和非组蛋白的方式参与基因的转录调控.同时,它们能在转录因子和基本转录复合物之间起到桥梁作用,而且也能为整合多种转录因子提供支架,是一种典型的转录辅激活子. p300/CBP与细胞周期调控、细胞凋亡以及癌症的发生等过程之间有着直接的联系。本文概括了p300/CBP与PCAF的基本特性,并简要介绍它们与其他蛋白之间的相互作用,特别是E1A的最新研究进展。     

Consolidation of proteomics data in the Cancer Proteomics database

Cancer is a class of diseases characterized by abnormal cell growth and one of the major reasons for human deaths. Proteins are involved in the molecular mechanisms leading to cancer, furthermore they are affected by anti‐cancer drugs, and protein biomarkers can be used to diagnose certain cancer types. Therefore, it is important to explore the proteomics background of cancer. In this report, we developed the Cancer Proteomics database to re‐interrogate published proteome studies investigating cancer. The database is divided in three sections related to cancer processes, cancer types, and anti‐cancer drugs. Currently, the Cancer Proteomics database contains 9778 entries of 4118 proteins extracted from 143 scientific articles covering all three sections: cell death (cancer process), prostate cancer (cancer type) and platinum‐based anti‐cancer drugs including carboplatin, cisplatin, and oxaliplatin (anti‐cancer drugs). The detailed information extracted from the literature includes basic information about the articles (e.g., PubMed ID, authors, journal name, publication year), information about the samples (type, study/reference, prognosis factor), and the proteomics workflow (Subcellular fractionation, protein, and peptide separation, mass spectrometry, quantification). Useful annotations such as hyperlinks to UniProt and PubMed were included. In addition, many filtering options were established as well as export functions. The database is freely available at http://cancerproteomics.uio.no .     

Costunolide Induces Apoptosis through Generation of ROS and Activation of P53 in Human Esophageal Cancer Eca‐109 Cells

Costunolide is a sesquiterpene lactone, which possesses potent anti‐cancer properties. However, there is little report about its effects on esophageal cancer. In our study, we investigated the effects of costunolide on the cell viability, cell cycle, and apoptosis in human esophageal cancer Eca‐109 cells. It was found that costunolide inhibited the growth of Eca‐109 cells in a dose‐dependent manner, which was associated with the loss of mitochondrial membrane potential (Δψ_m) and the production of ROS. Costunolide induced apoptosis of Eca‐109 cells as well as cell cycle arrest in G1/S phase by upregulation of P53 and P21. Costunolide triggered apoptosis in esophageal cancer cells via the upregulation of Bax, downregulation of Bcl‐2, and significant activation of caspase‐3 and poly ADP‐ribose polymerase. These effects were markedly abrogated when cells were pretreated with N‐acetylcysteine, a specific reactive oxygen specie inhibitor. These results suggest that costunolide is a potential candidate for the treatment of esophageal cancer.     

Molecular mechanism underlying the selective attack of trehalose lipids on cancer cells as revealed by coarse-grained molecular dynamics simulations

The present study indicated that the mixed lipid bilayer of dimyristoylphosphatidylcholine (DMPC) and trehalosemonomyristate (TreC14) interacted strongly with the plasma membrane of cancer cells, and not that of normal cells, when the composition of TreC14 was 70%, as revealed by coarse-grained molecular dynamics simulations. These results were consistent with those of previous experimental studies, indicating that DMPC/TreC14 mixed liposomes (DMTreC14) with TreC14 composition at 70% exhibited a strong anti-cancer effect without affecting normal cells. The simulations also revealed that lipids with highly hydrophilic and bulky head groups, such as TreC14, phosphatidylinositol (PI), and phosphatidylserine (PS), showed the tendency to accumulate. This caused both the DMTreC14 and cancer cell membranes to bend into large positive curvatures, resulting in tight contact between them. In contrast, no apparent interaction between the DMTreC14 and normal cell membranes was observed because PI and PS did not exist in the extracellular monolayer of the normal cell membrane.     

Aqueous biphasic cancer cell migration assay enables robust,high‐throughput screening of anti‐cancer compounds

Migration of tumor cells is a fundamental event implicated in metastatic progression of cancer. Therapeutic compounds with the ability to inhibit the motility of cancer cells are critical for preventing cancer metastasis. Achieving this goal requires new technologies that enable high‐throughput drug screening against migration of cancer cells and expedite drug discovery. We report an easy‐to‐implement, robotically operated, cell migration microtechnology with the capability of simultaneous screening of multiple compounds. The technology utilizes a fully biocompatible polymeric aqueous two‐phase system to pattern a monolayer of cells containing a cell‐excluded gap that serves as the migration niche. We adapted this technology to a standard 96‐well plate format and parametrically optimized it to generate highly consistent migration niches. The analysis of migration is done automatically using computerized schemes. We use statistical metrics and show the robustness of this assay for drug screening and its sensitivity to identify effects of different drug compounds on migration of cancer cells. This technology can be employed in core centers, research laboratories, and pharmaceutical industries to evaluate the efficacy of compounds against migration of various types of metastatic cancer cells prior to expensive animal tests and thus, streamline anti‐migratory drug screening.     

Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line

Objectives: Although emerging data suggest that zoledronic acid (Zol) may have different anti‐tumour activities against a broad range of cancers, its effects on lung cancer remain largely unknown. The aim of this study was to evaluate in vitro the anti‐tumoural and anti‐angiogenetic effect of zoledronic acid in non‐small‐cell lung cancer (NSCLC) cells. Material and methods: We treated A549 NSCLC cells with zoledronic acid to investigate survival, cell cycle activity, anti‐angiogenic activity and apoptotic responses to it. Results: We observed that highest Zol concentration (100 μm ) caused arrest in G1 phase of the cell cycle and also induced different percentages of apoptosis in presence (0.9% versus 4.4%) or absence (2.4% versus 28.5%) of serum (P = 0.0001). Zol concentration from 5 to 100 μm for 2 days induced significant concentration‐dependent cell death in adherent cells. Furthermore, Zol (10–100 μm ) induced dose‐dependent reduction both of mRNA and protein expression of VEGF associated with parallel decrease in VEGF secretion in the culture medium. Conclusion: Taken together, these results support a possible anti‐cancer and anti‐angiogenetic activity of Zol. Our data may not only provide a basis for the clinical use of this drug as preventive agent of bone metastases but also suggest that Zol deserves attention as an anti‐cancer agent in non‐small‐cell lung cancer.     

Enhancing FTS (Salirasib) efficiency via combinatorial treatment

The Ras oncogene transmits signals, which regulate various cellular processes including cell motility, differentiation, growth and death. Since Ras signalling is abnormally activated in more than 30% of human cancers, Ras and its downstream signalling pathways are considered good targets for therapeutic interference. Ras is post‐translationally modified by the addition of a farnesyl group, which permits its attachment to the plasma membrane. Exploiting this knowledge, a synthetic Ras inhibitor, S‐trans, trans‐farnesylthiosalicylic acid (FTS; Salirasib), was developed. FTS resembles the farnesylcysteine group of Ras, and acts as an effective Ras antagonist. In the present review, the effect of FTS in combination with various other drugs, as tested in vitro and in vivo, and its therapeutic potential are discussed. As reviewed, FTS cooperates with diverse therapeutic agents, which significantly improves treatment outcome. Therefore, combinations of FTS with other agents have a potential to serve as anti‐cancer or anti‐inflammatory therapies.     

Single-cell analysis of tumors: Creating new value for molecular biomarker discovery of cancer stem cells and tumor-infiltrating immune cells

Biomarker-driven individualized treatment in oncology has made tremendous progress through technological developments, new therapeutic modalities and a deeper understanding of the molecular biology for tumors, cancer stem cells and tumor-infiltrating immune cells. Recent technical developments have led to the establishment of a variety of cancer-related diagnostic, prognostic and predictive biomarkers. In this regard, different modern OMICs approaches were assessed in order to categorize and classify prognostically different forms of neoplasia. Despite those technical advancements, the extent of molecular heterogeneity at the individual cell level in human tumors remains largely uncharacterized. Each tumor consists of a mixture of heterogeneous cell types. Therefore, it is important to quantify the dynamic cellular variations in order to predict clinical parameters, such as a response to treatment and or potential for disease recurrence. Recently, single-cell based methods have been developed to characterize the heterogeneity in seemingly homogenous cancer cell populations prior to and during treatment. In this review, we highlight the recent advances for single-cell analysis and discuss the challenges and prospects for molecular characterization of cancer cells, cancer stem cells and tumor-infiltrating immune cells.     

Killing cancer with platycodin D through multiple mechanisms

Cancer is a multi‐faceted disease comprised of a combination of genetic, epigenetic, metabolic and signalling aberrations which severely disrupt the normal homoeostasis of cell growth and death. Rational developments of highly selective drugs which specifically block only one of the signalling pathways have been associated with limited therapeutic success. Multi‐targeted prevention of cancer has emerged as a new paradigm for effective anti‐cancer treatment. Platycodin D, a triterpenoid saponin, is one the major active components of the roots of Platycodon grandiflorum and possesses multiple biological and pharmacological properties including, anti‐nociceptive, anti‐atherosclerosis, antiviral, anti‐inflammatory, anti‐obesity, immunoregulatory, hepatoprotective and anti‐tumour activities. Recently, the anti‐cancer activity of platycodin D has been extensively studied. The purpose of this review was to give our perspectives on the current status of platycodin D and discuss its anti‐cancer activity and molecular mechanisms which may help the further design and conduct of pre‐clinical and clinical trials to develop it successfully into a potential lead drug for oncological therapy. Platycodin D has been shown to fight cancer by inducing apoptosis, cell cycle arrest, and autophagy and inhibiting angiogenesis, invasion and metastasis by targeting multiple signalling pathways which are frequently deregulated in cancers suggesting that this multi‐target activity rather than a single effect may play an important role in developing platycodin D into potential anti‐cancer drug.     

Astragalus membranaceus lectin (AML) induces caspase-dependent apoptosis in human leukemia cells

Objectives: Recently, plant lectins have attracted great interest due to their various biological activities such as anti‐cancer, anti‐fungal and anti‐viral activities. We have reported earlier concerning anti‐proliferation of human cancer cell lines by a galactose‐binding lectin (AML), from a Chinese herb, Astragalus membranaceus. In the present study, detailed investigations into the mechanism of such anti‐proliferation properties have been carried out. Materials and methods: Mechanism of apoptosis initiation in K562 cells by AML was investigated by morphology, flow cytometry and western blot analysis. Results: AML induced apoptosis in a caspase‐dependent manner in the chronic myeloid leukemia cell line, K562. Furthermore, we observed that cytotoxicity and apoptosis of K562 cells induced by AML were completely abolished in presence of lactose or galactose. Conclusions: Our results suggest that AML could act as a potential anti‐cancer drug.     

Effects of kinetin riboside on proliferation and proapoptotic activities in human normal and cancer cell lines

Kinetin riboside (KR) is a N6‐substituted derivative of adenosine. It is a natural compound which occurs in the milk of coconuts on the nanomole level. KR was initially shown to selectively inhibit proliferation of cancer cells and induce their apoptosis. We observed that KR inhibited growth (20–80%) of not only human cancer, but also normal cells and that this effect strongly depended on the type of cells. The anti‐apoptotic Bcl‐2 protein was downregulated, while proapoptotic Bax was upregulated in normal as well as in cancer cell lines, upon exposure to KR. Cytochrome c level increased in the cytosol upon treatment of cells with KR. The activity of caspases (ApoFluor®Green Caspase Activity Assay), as well as caspase‐3 (caspase‐3 activation assay) were increased mainly in cancer cells. The expression of procaspase 9 and its active form in the nucleus as well as in cytosol of KR‐treated cells was elevated. In contrast, no effect of KR on caspase 8 expression was noted. The results indicated that non‐malignant cells were less sensitive to KR then their cancer analogs and that KR most likely stimulated apoptosis mechanism of cancer cells through the intrinsic pathway. J. Cell. Biochem. 112: 2115–2124, 2011. © 2011 Wiley‐Liss, Inc.